Apricus Biosciences Announces the Launch of Its Novel

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Belgium by Sandoz

SAN DIEGO, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced the launch of Vytaros ® in Belgium by the Sandoz Division of the Novartis Group of Companies ("Sandoz"). Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"), being marketed in Belgium as Vytaros, is also marketed in other European countries as Vitaros ® . Belgium will be the third territory in which Sandoz is launching the product in the European Union (the "EU"), following successful launches by Apricus' partners Takeda in the United Kingdom (the "UK"), and by Sandoz in Germany and Sweden. The product is currently approved in ten countries in Europe, including major ED markets such as the aforementioned and France, Italy and Spain. The Company expects additional launches by its partners in these approved countries into 2015.

Richard Pascoe, Chief Executive Officer of Apricus, commented, "We are pleased to announce the launch of our novel ED treatment, Vitaros, in Belgium by our partner Sandoz following their successful introduction of the product in Germany and Sweden earlier this year. This launch represents Sandoz' continued commitment to our partnership and to this medical need." Mr. Pascoe continued, "Moreover, we look forward to additional launches of Vitaros into 2015 by our partners, including Sandoz, in the remaining European territories where Vitaros is approved."

According to the most recent estimates, the European ED market in 2013 was above $1.3 billion, and analyst estimates for ex-US sales of the product are approximately $300 million at peak.

In December 2013, Apricus expanded its exclusive license agreement with Hexal AG, an affiliate within Sandoz, for the commercialization of the product in Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the Netherlands, Norway, Sweden and Switzerland (the "Expanded Territory") in addition to Germany. Under the terms of the agreement, Apricus is eligible to receive up to approximately $63 million from Sandoz in upfront, regulatory, launch and sales milestone payments for the product in Germany and the Expanded Territory, which includes up to $4.5 million in new upfront and launch milestone compensation for the Expanded Territory. The successful launch of Vytaros in Belgium results in a $500,000 launch milestone payment to Apricus.

Apricus continues to receive multiple commercial product orders of Vitaros from its partners, and is currently manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe. The commercialization of the product has been fully licensed to these partners, with Apricus positioned to earn tiered double-digit royalties and more than $200 million in potential milestone payments.

About Apricus Biosciences, Inc .

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines to meet the needs of patients. The Company's lead product, Vitaros ® , for the treatment of erectile dysfunction, is approved in Europe and Canada and commercialized in several countries in Europe. Apricus' marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second-generation Vitaros room temperature device is under development and is expected to enhance the product's commercial value. The Company recently initiated a Phase 2a trial for RayVa ™ , the Company's product candidate for the treatment of Raynaud's phenomenon. Femprox ® , the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox. In October 2014, Apricus gained U.S. development and commercialization rights for fispemifene, a selective estrogen receptor modulator, in Phase 2 development.

For further information on Apricus, visit www.apricusbio.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended.  Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: references to the timing of planned launches and initial shipments of Vytaros ® /Vitaros ® in various countries by Apricus' commercial partners; the potential for the product to achieve commercial success generally or in any specific territory; and the size of the commercial opportunity for the product, particularly in Belgium. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of the Company, including, but not limited to: Apricus' dependence on its commercial partners, such as Sandoz, to carry out the commercial launch of the product in various territories, and the potential for delays in the timing of commercial launch; competition in the ED market and other markets in which Apricus and its partners operate; Apricus' ability to obtain and maintain intellectual property protection for product; Apricus' ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; and market conditions.  These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.

Steve Martin Apricus Biosciences Chief Financial Officer (858) 222-8041 Investors: Angeli Kolhatkar Media: Justin Jackson Burns McClellan (212) 213-0006 Retail: Chris Eddy, David Collins Catalyst Global (212) 924-9800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 0

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 159

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 71

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 40

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 255

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 0

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Symbotic Inc. Faces Legal Challenges Amid Financial Irregularities

Updated Category News Views 138

Symbotic Inc. Under Investigation for Securities Violations There has been a significant development for investors of Symbotic Inc. As concerns about the Company’s financial practices have arisen, the Schall Law Firm has initiated an investigation. This effort is aimed at ensuring shareholders are informed and protected amid allegations of misleading statements related...

Continue Reading
Turning Point Brands: Growth Opportunities Ahead with New Rating

Updated Category News Views 103

Turning Point Brands Gets a Positive Buy Rating Recently, Turning Point Brands (NYSE: TPB) earned a favorable Buy rating from Roth/MKM, along with a price target set at $50. This company is known for its wide range of consumer brands in the nicotine, tobacco, and cannabis markets, particularly recognized for its popular rolling papers and moist snuff products. Growth in...

Continue Reading
NeuroSense Therapeutics Celebrates Key Manufacturing Milestone

Updated Category News Views 232

NeuroSense Therapeutics Achieves Commercial Manufacturing Scale-Up NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a pioneering biotechnology firm dedicated to developing innovative treatments for severe neurodegenerative diseases, has announced a major milestone in its commercial journey. The company has successfully scaled up its production of PrimeC, preparing for...

Continue Reading
Discover the Potential of Azapeptides in Peptide Stability

Updated Category News Views 179

Unveiling the Future of Peptide Stability with Azapeptide Synthesis In this informative webinar, participants will discover how strategies involving azapeptides can significantly enhance the stability of peptides and improve workflows related to synthesis. Attendees will delve into techniques for incorporating aza-amino acids within peptides that utilize traditional amino...

Continue Reading
Ascent Solar Technologies Faces Major Challenges in Market

Updated Category News Views 118

Ascent Solar Technologies Hits 52-Week Low Ascent Solar Technologies, recognized for its cutting-edge thin-film photovoltaic modules, is currently going through a challenging period. The company's stock has reached a 52-week low of $2.32, reflecting an astonishing nearly 99.6% decline over the past year. This drastic drop underscores the significant hurdles the company...

Continue Reading